Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual MeetingGlobeNewsWire • 09/15/22
Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDAGlobeNewsWire • 09/12/22
Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic RetinopathyGlobeNewsWire • 09/08/22
Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate UpdateGlobeNewsWire • 08/12/22
Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in AugustGlobeNewsWire • 08/08/22
Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent IssuanceGlobeNewsWire • 08/03/22
Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in JulyGlobeNewsWire • 07/07/22
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 PublicationGlobeNewsWire • 06/29/22
Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society MeetingGlobeNewsWire • 06/08/22
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision DisturbancesGlobeNewsWire • 05/19/22
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate UpdateGlobeNewsWire • 05/13/22
Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/11/22
Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of MydriasisGlobeNewsWire • 04/28/22
Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022GlobeNewsWire • 04/26/22
Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and EyeceleratorGlobeNewsWire • 04/19/22
Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MAGlobeNewsWire • 04/06/22
Ocuphire Pharma's Shares Fall Despite Positive Data From Registrational Phase 3 Trial Of NyxolBenzinga • 03/29/22
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of MydriasisGlobeNewsWire • 03/29/22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate UpdateGlobeNewsWire • 03/24/22
Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic RetinopathyGlobeNewsWire • 03/16/22
Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of MydriasisGlobeNewsWire • 03/08/22
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference PresentationsGlobeNewsWire • 02/08/22
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D DayGlobeNewsWire • 01/31/22